We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+14.35%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.65B
AUM Growth
+$205M
Cap. Flow
-$69.3M
Cap. Flow %
-2.62%
Top 10 Hldgs %
39.13%
Holding
181
New
13
Increased
25
Reduced
35
Closed
9

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$17.1M
2
PFE icon
Pfizer
PFE
+$15.6M
3
BIIB icon
Biogen
BIIB
+$14.1M
4
MCK icon
McKesson
MCK
+$12.2M
5
AVTR icon
Avantor
AVTR
+$9.51M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$26.5M
2
JNJ icon
Johnson & Johnson
JNJ
+$24.9M
3
HUM icon
Humana
HUM
+$18.5M
4
AZN icon
AstraZeneca
AZN
+$15.7M
5
MOH icon
Molina Healthcare
MOH
+$15.6M

Sector Composition

Rank Sector Weight
1 Healthcare 97.55%
2 Real Estate 1.68%
3 Industrials 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XLV icon
176
State Street Health Care Select Sector SPDR ETF
XLV
$41.8B
– –
-29,024
Closed -$3.52M
CCXI
177
DELISTED
ChemoCentryx, Inc.
CCXI
– –
-78,197
Closed -$4.04M
ENDP
178
DELISTED
Endo International plc
ENDP
– –
-494,607
Closed -$48K
BHVN
179
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
– –
-70,176
Closed -$10.6M
4 5 6 7
8

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q4 2022 Portfolio in Review

As of Q4 2022, Tekla Capital Management held 181 positions worth $2.65B, up 8.4% from $2.44B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Tekla Capital Management's Q4 2022 filing shows 13 new, 25 increased, 35 reduced and 9 closed positions. Its largest new stake was Avantor: 459,488 shares worth $9.69M. The largest sale was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $26.5M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Real Estate and Industrials.

  • Tekla Capital Management's largest Q4 2022 buy was Avantor: 459,488 shares worth $9.69M.
  • Tekla Capital Management added most to Eli Lilly in Q4 2022, an estimated $17.1M increase.
  • Tekla Capital Management's biggest Q4 2022 reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, cutting an estimated $26.5M.
  • Tekla Capital Management fully exited Biohaven Pharmaceutical Holding Company Ltd. in Q4 2022, selling an estimated $10.6M.
  • Tekla Capital Management's ten largest holdings make up 39% of its $2.65B portfolio in Q4 2022.
  • Tekla Capital Management opened 13 new positions and closed 9 in Q4 2022.
  • Tekla Capital Management's portfolio value rose 8.4% quarter-over-quarter to $2.65B.

Based on Tekla Capital Management's 13F filing for Q4 2022, filed 10 Feb 2023.